Miconazole is a broad-spectrum antifungal used in topical preparations. In the present investigation the minimal inhibitory concentration (MIC) of miconazole for eighty wild type strains of gram-positive and gram-negative bacteria isolated from infected skin lesions was assessed using a modified agar dilution test (adapted to CLSI, Clinical Laboratory Standards Institute). 14 ATCC reference strains served as controls.
| INTRODUCTION
Topical antimicrobial therapy is an important alternative to systemic antibacterial therapy in particular in the management of superficial bacterial skin infections and superinfected or impetiginised eczema, which are mainly caused by gram-positive bacteria.
In contrast to systemic therapy, advantages of topically applied antibiotics are the immediate onset of action, generation of higher concentrations at the site of infection and the reduction or lack of systemic side effects. 1, 2 On the other hand topical therapy with antibiotics is seen very critical because of the risk of contact sensitisation, delayed wound repair, resorptive toxicity and promotion of bacterial resistance. 1, 4 Another option for topical antimicrobial therapy could be the use of antiseptics. The effect of antiseptics is based on a physico-chemical destruction of cell walls or denaturisation of proteins. They have a broader spectrum and a faster onset of action than topically applied antibiotics. Development of resistance is seen very rarely. 1 On the contrary they are only effective within a narrow therapeutic range: lower concentrations lack efficacy and higher concentrations may cause toxic effects and delayed wound healing.
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Interestingly azole antimycotics have been shown to also exert antibacterial effects 5 and new formulations for skin diseases have been suggested. 6 Especially the broad-spectrum imidazole antifungal miconazole was found to be effective against skin infections caused by gram-positive bacteria both in vitro and in vivo. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The present investigation aimed to determine the efficacy of miconazole against bacteria currently isolated from superficial skin lesions and infections using a modified standardised agar dilution test in order to show whether miconazole could be a therapeutic alternative even in the management of difficult to treat bacteria, esp. methicillin-and fusidic acidresistant Staphylococcus aureus isolates.
| MATERIALS AND METHODS
Miconazole pure substance was provided by Almirall Hermal GmbH, Reinbek, Germany. To prepare a stock solution of 4 mg/mL for further testing 20 mg of miconazole were dissolved in a mixture of 2 mL dimethylsulfoxide (DMSO, Hollborn, Leipzig, Germany) and 3 mL sterile aqua destillata.
| Strains and media
In order to determine the antibacterial activity of miconazole eighty wild type strains as well as fourteen reference strains as controls were included (Tables 1 and 2 The following strains were investigated as detailed in Table 1 .
The 14 ATCC reference strains used as controls are summarised in [21] [22] [23] [24] with the restriction that this method was standardised for sensitivity testing of bacteria against antibiotics. In more detail the agar dilution test was based on the method recently described by Clark et al. [16] . 
| Inocula
Bacteria were suspended in sterile saline to get a density of 10 
| RESULTS

Pseudomonas aeruginosa (3)
Klebsiella oxytoca (4) Acinetobacter baumannii (2) (A-streptococci) (8) were found to be slightly more sensitive (0.78-1.563 μg/mL). Among the species tested Corynebacteria spp. were found to be most sensitive. 
| DISCUSSION
The imidazole antifungal miconazole is a broad-spectrum antifungal agent widely used in the topical therapy of superficial mycotic infections. [7] [8] [9] [10] In the present in vitro study this azole was found to In this study some of the Corynebacteria spp. showed excellent sensitivity against miconazole with MICs ranged from (<0.024) 0.049 to 0.78 μg/mL after 24 h of incubation and 0.097 to 3.125 μg/mL after 48 h (Table 3 , Figure 1A ,B). These results are in accordance with the data published by Nenoff et al., [18] who found Corynebacteria to be susceptible to bifonazole with MICs of 0.05 to 1.56 μg/mL.
In our study no inhibitory effect of miconazole was found against the gram-negative bacteria within the concentrations and incubation periods tested (MIC >200 μg/mL). The results were confirmed by the MICs determined with the ATCC reference strains and are well in line with the data published by Pietschmann et al. [14, 15] .
Azoles like the imidazole miconazole exert their antifungal effects by inhibition of the cytochrome p450 dependent enzyme lanosterol-14-demethylase which is essential for the ergosterol synthesis in fungi. [7] [8] [9] 25 The antibacterial effect might be based on the presence of 14α-sterol-demethylase-homologues in staphylococci. 5, 25 More recent data correlated the antibacterial activity with the inhibition of bacterial flavohaemoglobins. 26, 27 They play a key role in bacterial resistance to nitrosative stress and NO signalling modulation. Remarkably, not all azole derivatives exhibit similar effects. Thus in a study by Sugita et al. on the in vitro activities of azole antifungal agents against propionibacterium acnes, fluconazole and voriconazole showed no anti-P. acnes activity with the concentrations tested.
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In this study a broad spectrum of bacterial pathogens important for skin diseases was tested. matology where infections are often mixed. 6 As topical skin medications with a broad, non-resistance-promoting activity, they have a very low potency of causing contact allergy in contrast to antibiotics. 32, 33 Furthermore, in combination with topical corticosteroids miconazole can be a valuable option in the treatment of limited superficial infections such as S. aureus-mediated flare-ups of atopic dermatitis or other kind of superinfected eczema by restoring the defective skin barrier more rapidly.
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One problem with the present and other MIC studies is the difficulty of interpreting and applying in vitro data to the in vivo situation. Specifically, it is hard to transform a MIC value in μg/mL obtained with the agar dilution assay into dosing suggestions for the amount of cream to be applied in order to reach a similar concentration on the skin.
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The in vitro data suggest that miconazole could be a useful therapeutic option for superficial infections also caused by resistant staphylococci. However, in vivo environments can differ greatly influenced by several factors such as pH, salt concentrations and temperature. Therefore a proper clinical investigation is required.
However, the low MICs against staphylococci and corynebacteria are likely to be exceeded by topical therapy. This may also apply to anaerobes esp. propionibacterium acnes, although the MIC found is somewhat higher. Miconazole in a 2% cream formulation generates relatively high local concentrations of the active substance.
